Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy
Retrieved on:
Friday, February 11, 2022
Health, Clinical Trials, General Health, Pharmaceutical, Optical, Biotechnology, Patient, Quality of life, Food, European Medicines Agency, Cell death, Company, HIV disease progression rates, Forward-looking statement, U.S. Securities and Exchange Commission, Retinal pigment epithelium, Security (finance), Private Securities Litigation Reform Act, Vance DeGeneres, Nasdaq, ISEE, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Complement component 5, C5, Group of Five, MAC, Population, Geographic atrophy, AMD, Disease, Natural history, Food and Drug Administration, Angiogenesis, Growth, Research, Multimedia, Retina, Epithelium, Doctor of Pharmacy, C5a, Pharmaceutical industry, MD, Ophthalmology, GATHER1 and GATHER2, Zimura, Iveric Bio, GATHER1 AND GATHER2, ZIMURA, IVERIC BIO
This analysis supports our expectation that we would see a greater reduction in growth away from the foveal center, reflecting the circumferential growth pattern typical for GA patients.
Key Points:
- This analysis supports our expectation that we would see a greater reduction in growth away from the foveal center, reflecting the circumferential growth pattern typical for GA patients.
- Geographic atrophy has a major impact on functional vision which could alter the quality of life and independence of affected individuals, stated Pravin U. Dugel, MD, President of Iveric Bio.
- The results of this subgroup analysis are consistent with the primary analysis results in the intent to treat population.
- The Company previously announced that GATHER1 showed Zimura (avacincaptad pegol) met its pre-specified primary efficacy endpoint with statistical significance in the Phase 3 clinical trial.